Eli Lilly announced in December that it will acquire Ventyx Biosciences, gaining an advanced GLP-1/glucagon dual agonist candidate currently in Phase 2 trials for obesity and type 2 diabetes. The target molecule demonstrated average weight-loss responses of 15% in mid-stage studies and achieved statistically significant HbA1c reductions of 1.8 percentage points versus placebo. Analysts estimate that, if approved, this asset could add up to $5 billion in annual sales by 2030, further bolstering Lilly’s market leadership established by tirzepatide.

On January 12, Lilly and Nvidia committed up to $1 billion over five years to build an AI innovation lab in the San Francisco Bay area. The joint facility will combine Lilly’s clinical and chemical data sets with Nvidia’s Vera Rubin AI processors to train models aimed at cutting drug discovery timelines from over a decade to under five years. This follows Lilly’s creation of the industry’s largest pharma supercomputer in 2024 and the launch of TuneLab, an AI platform that has already supported data analysis for more than 20 biotech collaborations.

In Q3, Lilly’s revenue climbed 54% year-over-year to $17.6 billion, while adjusted EPS surged 480% to $6.21. Tirzepatide became the world’s top-selling medicine during the quarter, driving 30% of total growth. Beyond weight management, Lilly is advancing orforglipron—an oral obesity candidate now awaiting an FDA decision expected in April—which could compete directly with existing GLP-1 injectables. The company’s dividend has risen by 103.5% over the past five years, underpinned by more than $10 billion in annual free cash flow, and its pipeline diversification includes recent approvals in oncology, immunology and Alzheimer’s therapies.